



CEO Resignation

Melbourne, Australia – 16 January 2024: Adherium Limited (ASX:ADR) a leader in digital health technologies, advises that Rick Legleiter has tendered his resignation as Chief Executive Officer, and has provided six months' notice to enable a smooth transition to new leadership.

Mr Legleiter joined the business in May 2021 during the height of the COVID-19 pandemic. Since that time, he has led successful regulatory filings, next generation product launches and a focus on a go-to-market strategy leading to multiple agreements with major US commercial partners.

Commenting on his resignation, Mr Legleiter said, "I staunchly believe our reimbursed digital technology helps respiratory patients live better lives while reducing healthcare costs and I am convinced we have opened the door to success for the Company's commercial strategy. While leaving for family reasons, I thank shareholders, the Board, my leadership team, and all employees for the honour of serving."

Mr Lou Panaccio, Chairman of the Board, is stepping into the Executive Chairman role as the Board will use this opportunity for talent acquisition as the business continues its growth trajectory, including an executive search for a new CEO. Mr Panaccio commented, "I would like to thank Rick on behalf of Adherium and our entire team for his professionalism and contributions. Rick became CEO during the global lockdown due to COVID-19, a particularly challenging time, and has helped the company through an important transformational stage and key fund-raising round. I appreciate Rick's support to work closely with me during the transitional period and wish him and his family well."

ENDS-

This ASX announcement was approved and authorised for release by the Board of Adherium.

Enquiries:
Rick Legleiter
CEO
Adherium Limited
investors@adherium.com

About Adherium

Adherium Limited (ASX: ADR) is a digital health company providing solutions for improving patient treatment with remote monitoring and data solutions. Its Hailie® system is transforming management of chronic respiratory conditions, especially asthma and chronic obstructive pulmonary disease. Hailie improves patient health through better adherence and self-management while enabling doctors to be paid for remote work and saving costs across health systems by avoiding hospital admissions. Adherium's clinically proven sensors, app and powerful data platform provide remote, real-time, personalised information to patients and clinicians. Adherium is increasing sales in US and other markets by pursuing partnerships with major hospital systems, medical groups and insurers. For more information, visit <https://www.adherium.com/>